Cochlear Limited
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Diggory William Howitt
- Full Time Employees
- 4,996
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 1 University Avenue Sydney NSW Australia 2109
- IPO Date
- Apr 5, 2010
- Website
- cochlear.com
- Similar Companies
- Business
- Cochlear Limited is a global leader in the design, manufacture, and sale of implantable hearing solutions. The company’s core products include cochlear implants, bone conduction implants, acoustic implants, and associated sound processors, accessories, and wireless communication devices. Cochlear offers a range of hearing solutions under prominent brands such as Nucleus®, Baha®, and Osia®, targeting individuals with moderate to profound hearing loss. The company operates primarily in the healthcare industry, focusing on medical devices and hearing implant technology. Cochlear’s products are distributed and supported in markets worldwide, including North America, Europe, Asia-Pacific, and Latin America. Founded in 1981, Cochlear Limited is headquartered in Sydney, Australia. Recent major developments for Cochlear include strategic expansions in product offerings and partnerships aimed at enhancing hearing healthcare. Over the last 1-2 years, Cochlear has introduced new advanced implant technologies and sound processors that integrate with digital and wireless technologies to improve user experience. The company has strengthened its global commercial presence through partnerships with hearing healthcare providers and has focused investments on research and development for next-generation hearing technologies. Additionally, Cochlear continues to expand its service offerings for post-implant care and rehabilitation support, consolidating its position as a comprehensive hearing solutions provider. Cochlear operates through multiple business segments covering product development, manufacturing, distribution, and aftercare services. Its target market encompasses healthcare professionals, audiologists, and individuals with hearing impairment, with an emphasis on accessibility and technology innovation across diverse geographic regions. Subsidiaries and affiliates operate internationally, supporting Cochlear's global supply chain and customer service capabilities. The company remains committed to advancing hearing implant technology through continued innovation and strategic growth initiatives.
Better Hearing and Whole-Body Health: What to Know About MRI Access with Cochlear Implants
Envoy Medical Reports Landmark Accomplishments, Advancing Toward FDA Approval of First-of-Its-Kind Fully Implanted Cochlear Implant
MED-EL USA Presents Real World Clinical Insights to Support Tailored Hearing Solutions at the 2026 American Cochlear Implant Association Meeting
Cochlear Limited (CHEOY) Q3 2026 Sales/Trading Call Transcript
Australia's Cochlear crashes 40% after flagging weak demand and Mideast war impact
Head-To-Head Survey: DocGo (NASDAQ:DCGO) vs. CochLear (OTCMKTS:CHEOY)
Envoy Medical Announces First Patients Successfully Reaching 12-Month Endpoint in Pivotal Clinical Trial for Fully Implanted Cochlear Implant
Envoy Medical Completes Enrollment of Pivotal Clinical Trial Evaluating First-Of-Its-Kind Fully Implanted Cochlear Implant
CochLear (OTCMKTS:CHEOY) and Sonic Healthcare (OTCMKTS:SKHHY) Financial Review
Cochlear North America Celebrates International Cochlear Implant Day with Announcement of 2026 Academic Scholarship Recipients
Cochlear Limited (CHEOY) Q2 2026 Earnings Call Transcript
Cochlear Announces Availability of Nucleus Nexa System to US Military Veterans
CochLear (OTCMKTS:CHEOY) versus Biodesix (NASDAQ:BDSX) Head-To-Head Review
MRI 3T Cochlear Implant Market Poised for 9.96% CAGR Growth, North America Leads
MED-EL Cochlear Implant Becomes First FDA-Approved Option for Children Seven Months and Older
Envoy Medical Secures New U.S. Patent for Innovative Cochlear Implant System Featuring a Removable Earplug Sensor and an Implanted Battery
Envoy Medical Marks Three-Year Anniversary of First Patient Receiving Its Breakthrough Fully Implanted Cochlear Implant
Envoy Medical Expands Patent Portfolio by Securing Additional European Patent for Breakthrough Cochlear Implant Technology
Envoy Medical Successfully Reaches Three-Month Follow-Up Milestone in Clinical Trial of the Acclaim Fully Implanted Cochlear Implant
Cochlear Limited (CHEOF) Q4 2025 Earnings Call Transcript